Late Stage Chronic Kidney Disease Drugs Market Scope And Analysis

  • Report Code : TIPRE00013768
  • Category : Life Sciences
  • No. of Pages : 150
Buy Now

Late Stage Chronic Kidney Disease Drugs Market Scope 2031

Buy Now

Late Stage Chronic Kidney Disease Drugs Market Report Late Stage Chronic Kidney Disease Drugs Market Size and Share Late Stage Chronic Kidney Disease Drugs Market Scope and Analysis

Late Stage Chronic Kidney Disease Drugs Market Report Scope

Report Attribute Details
Market size in 2021 US$ 5.74 Billion
Market Size by 2031 US$ 17.95 Billion
Global CAGR (2023 - 2031) 12.2%
Historical Data 2021-2022
Forecast period 2024-2031
Segments Covered By Product Type
  • Potassium Binders
  • Calcimimetics
  • Calcium-Based Phosphate Binders
  • Vitamin D
  • Sterols
By Indication
  • Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
  • Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
  • Late Stage Chronic Kidney Disease Induced Hyperkalaemia
By Distribution Channel
  • Online Pharmacies
  • Hospital Pharmacies
  • Retail Pharmacies
Regions and Countries Covered North America
  • US
  • Canada
  • Mexico
Europe
  • UK
  • Germany
  • France
  • Russia
  • Italy
  • Rest of Europe
Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
South and Central America
  • Brazil
  • Argentina
  • Rest of South and Central America
Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa
Market leaders and key company profiles
  • AbbVie Inc
  • Amgen
  • AstraZeneca
  • Sanofi
  • Kyowa Kirin Co Ltd
  • Takeda Pharmaceutical Company Limited
  • Astellas Pharma Inc
  • Bayer AG
  • Vifor Pharma Management Ltd
  • Akebia Drugs Inc
    		•